Clinical data
Routes of
ATC code
  • None
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: Prescription only [1]
  • NZ: Prescription only [2]
  • UK: Unscheduled
  • US: Schedule I
  • UN: Unscheduled
CAS Number
PubChem CID
ECHA InfoCard 100.001.363
Chemical and physical data
Formula C20H26N2O
Molar mass 310.44 g·mol−1
3D model (JSmol)
Melting point 152 to 153 °C (306 to 307 °F)

Ibogaine is a naturally occurring psychoactive substance found in plants in the Apocynaceae family such as Tabernanthe iboga, Voacanga africana and Tabernaemontana undulata.[3] It is a psychedelic with dissociative properties.

Preliminary research indicates that it may help with drug addiction;[3] however, there is a lack of data in humans.[4] Its use has been associated with serious side effects and death.[3] It is used as an alternative medicine treatment for drug addiction in some countries. Its prohibition in other countries has slowed scientific research.[5] Ibogaine is also used to facilitate psychological introspection and spiritual exploration. Derivatives of ibogaine that lack the substance's psychedelic properties are under development.[6]

The psychoactivity of the root barks of Iboga tree, from which Ibogaine is extracted, was first discovered by the Pygmy tribe of Central Africa who passed the knowledge to the Bwiti tribe of Gabon. French explorers in turn learned it from the Bwiti tribe and brought Iboga back to Europe in 1899-1900 where it was subsequently marketed in France as Lambarene. Ibogaine-containing preparations are used for medicinal and ritual purposes within African spiritual traditions of the Bwiti, who claim to have learned it from the Pygmy peoples. Although it was first commonly advertised as having anti-addictive properties in 1962 by Howard Lotsof, its Western use predates that by at least a century. In France it was marketed as Lambarène and used as a stimulant. Additionally, the U.S. Central Intelligence Agency (CIA) studied the effects of ibogaine in the 1950s.[7]

Ibogaine is an indole alkaloid that is obtained either by extraction from the iboga plant or by semi-synthesis from the precursor compound voacangine,[8][9] another plant alkaloid. The total synthesis of ibogaine was described in 1956.[10] Structural elucidation by X-ray crystallography was completed in 1960.[11][12]

Psychoactive effects

Ibogaine is derived from the root of the Tabernanthe iboga, a plant known to exhibit psychedelic effects in its users.[13] The experience of Ibogaine is broken down in two phases, the visionary phase and the introspection phase. The visionary phase has been described as oneirogenic, referring to the dreamlike nature of its psychedelic effects, and lasts for 4 to 6 hours. The second phase, the introspection phase, is responsible for the psychotherapeutic effects. It can allow people to conquer their fears and negative emotions. Ibogaine catalyzes an altered state of consciousness reminiscent of dreaming while fully conscious and aware so that memories, life experiences, and issues of trauma can be processed.[14]



Ibogaine is not currently approved for any medical uses.[3] Clinical studies of ibogaine to treat drug addiction began in the early 1990s, but concerns about cardiotoxicity led to termination of those studies.[4] There is currently insufficient data to determine whether it is useful in treating addiction. Nonetheless, some alternative medicine clinics administer ibogaine for this purpose, in what has been called a "vast, uncontrolled experiment."[15] Clinical trials of Ibogaine for the treatment of alcoholism are currently underway in Brazil.[16]


In Bwiti religious ceremonies, the root bark is pulverized and swallowed in large amounts to produce intense psychoactive effects.[17]

Adverse effects


One of the first noticeable effects of large-dose ibogaine ingestion is ataxia, a difficulty in coordinating muscle motion which makes standing and walking difficult without assistance. Xerostomia (dry mouth), nausea, and vomiting may follow. These symptoms may be long in duration, ranging from 4 to 24 hours in some cases. Ibogaine is sometimes administered per rectum to avoid nausea and vomiting.


Ibogaine causes long QT syndrome at therapeutic doses, apparently by blocking hERG potassium channels in the heart.[3][18]


Work in the laboratory of Mark Molliver at Johns Hopkins indicated degeneration of cerebellar Purkinje cells observed in rats given substantially larger dosages of ibogaine than those used to study drug self-administration and withdrawal.[19] However, subsequent research found no evidence of neurotoxicity in the primate[20] or mouse[21] at dosages that produced cerebellar degeneration in the rat, and it has been suggested that cerebellar degeneration might be a phenomenon limited to a single species.[22] The FDA was aware of Molliver’s work at the time it approved a Phase 1 study in which humans received ibogaine in 1993.[23] Neuropathological examination revealed no evidence of degenerative changes in a woman who had received four separate doses of ibogaine ranging between 10 and 30 mg⁄ kg over a 15-month interval prior to her death due to a mesenteric artery thrombosis with small bowel infarction 25 days after her last ingestion of ibogaine.[20] A published series of fatalities temporally associated with the ingestion of ibogaine found no evidence suggesting a characteristic syndrome of neurotoxicity.[24]


Adverse interactions may occur between ibogaine and psychiatric medications. Some studies also suggest the possibility of adverse interaction with heart conditions.[18][3][24]

Because ibogaine is one of the many drugs that are partly metabolized by the cytochrome P450 complex, caution must be exercised to avoid foods or drugs that are similarly metabolized by CP450, in particular foods containing bergamottin or bergamot oil, such as grapefruit juice.[25]



Ibogaine (and metabolite)[26][27]
MOR 2,000–100,000700–3,000
DOR >100,0005,000–25,000
KOR 2,000–4,000600–1,000
5-HT2A 16,000>100,000
5-HT2C >10,000>10,000
5-HT3 2,600>100,000
σ1 2,500–9,00011,000–15,000
σ2 90–4005,000–19,000
NMDA 1,000–3,0006,000–15,000
nACh 201,500
SERT 50040
DAT 2,0002,000
Values are Ki (nM). The smaller the value, the
more strongly the drug binds to the site.

Ibogaine affects many different neurotransmitter systems simultaneously.[28][23]

Noribogaine is most potent as a serotonin reuptake inhibitor. It acts as a moderate κ-opioid receptor agonist[29] and weak µ-opioid receptor agonist[30] or weak partial agonist.[31] It is possible that the action of ibogaine at the kappa opioid receptor may indeed contribute significantly to the psychoactive effects attributed to ibogaine ingestion; Salvia divinorum, another plant recognized for its strong hallucinogenic properties, contains the chemical salvinorin A which is a highly selective kappa opioid agonist. Noribogaine is more potent than ibogaine in rat drug discrimination assays when tested for the subjective effects of ibogaine.[32]


Ibogaine is metabolized in the human body by cytochrome P450 2D6 into noribogaine (more correctly, O-desmethylibogaine or 12-hydroxyibogamine). Both ibogaine and noribogaine have a plasma half-life of around two hours in the rat,[33] although the half-life of noribogaine is slightly longer than that of the parent compound. It is proposed that ibogaine is deposited in fat and metabolized into noribogaine as it is released.[34] After ibogaine ingestion in humans, noribogaine shows higher plasma levels than ibogaine and is detected for a longer period of time than ibogaine.[35]


Ibogaine is a tryptamine. It has two separate chiral centers, meaning that there are four different stereoisomers of ibogaine. These four isomers are difficult to resolve.[36]


One recent total synthesis[37] of ibogaine and related drugs starts with 2-iodo-4-methoxyaniline which is reacted with triethyl((4-(triethylsilyl)but-3-yn-1-yl)oxy)silane using palladium acetate in DMF to form 2-(triethylsilyl)-3-(2-((triethylsilyl)oxy)ethyl)-1H-indole. This is converted using N-iodosuccinamide and then fluoride to form 2-(2-iodo-1H-indol-3-yl)ethanol. This is treated with iodine, triphenyl phosphine and imidazole to form 2-iodo-3-(2-iodoethyl)-1H-indole. Then using 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene and cesium carbonate in acetonitrile the ibogaine precursor 7-ethyl-2-(2-(2-iodo-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene is obtained. Using palladium acetate in DMF the ibogaine is obtained. If the exo ethyl group on the 2-azabicyclo[2.2.2]octane system in ibogaine is replaced with an endo ethyl then epiibogaine is formed.

Crystalline ibogaine hydrochloride is typically produced by semi-synthesis from voacangine in commercial laboratories.[17][38]


A synthetic derivative of ibogaine, 18-methoxycoronaridine (18-MC), is a selective α3β4 antagonist that was developed collaboratively by the neurologist Stanley D. Glick (Albany) and the chemist Martin E. Kuehne (Vermont).[39] This discovery was stimulated by earlier studies on other naturally occurring analogues of ibogaine such as coronaridine and voacangine that showed these compounds also have anti-addictive properties.[40][41]

Natural occurrence

Ibogaine occurs naturally in iboga root bark. Ibogaine is also available in a total alkaloid extract of the Tabernanthe iboga plant, which also contains all the other iboga alkaloids and thus has only about half the potency by weight as standardized ibogaine hydrochloride.[17]


The use of iboga in African spiritual ceremonies was first reported by French and Belgian explorers in the 19th century. The first botanical description of the Tabernanthe iboga plant was made in 1889. Ibogaine was first isolated from T. iboga in 1901 by Dybowski and Landrin[42] and independently by Haller and Heckel in the same year using T. iboga samples from Gabon. Complete synthesis of ibogaine was accomplished by G. Büchi in 1966.[43] Since then, several other synthesis methods have been developed.[44]

From the 1930s to 1960s, ibogaine was sold in France in the form of Lambarène, an extract of the Tabernanthe manii plant, and promoted as a mental and physical stimulant. The drug enjoyed some popularity among post World War II athletes. Lambarène was withdrawn from the market in 1966 when the sale of ibogaine-containing products became illegal in France.[45]

In the late 1960s the World Health Assembly classified ibogaine as a “substance likely to cause dependency or endanger human health,” the U.S. Food and Drug Administration (FDA) assigned it Schedule I classification, and the International Olympic Committee banned it as a potential doping agent.[46]

Anecdotal reports concerning ibogaine's effects appeared in the early 1960s.[47] Its anti-addictive properties were discovered accidentally by Howard Lotsof in 1962, at the age of 19, when he and five friends—all heroin addicts—noted subjective reduction of their craving and withdrawal symptoms while taking it.[48] Further anecdotal observation convinced Lotsof of its potential usefulness in treating substance addictions. He contracted with a Belgian company to produce ibogaine in tablet form for clinical trials in the Netherlands, and was awarded a United States patent for the product in 1985. The first objective, placebo-controlled evidence of Ibogaine's ability to attenuate opioid withdrawal in rats was published by Dzoljic et al. in 1988.[49] Diminution of morphine self-administration was reported in preclinical studies by Glick et al. in 1991.[50] Cappendijk et al. demonstrated reduction in cocaine self-administration in rats in 1993,[51] and Rezvani reported reduced alcohol dependence in three strains of "alcohol preferring" rats in 1995.[52]

As the use of ibogaine spread, its administration varied widely; some groups administered it systematically using well developed methods and medical personnel, while others employed haphazard and possibly dangerous methodology. Lotsof and his colleagues, committed to the traditional administration of ibogaine, developed treatment regimens themselves. In 1992, Eric Taub brought ibogaine to an offshore location close to the United States, where he began providing treatments and popularizing its use.[53] In Costa Rica Lex Kogan, another leading proponent, joined Taub in systematizing its administration. The two men established medically monitored treatment clinics in several countries.[54]

In 1981 an unnamed European manufacturer produced 44 kg of iboga extract. The entire stock was purchased by Carl Waltenburg, who distributed it under the name "Indra extract" and used it in 1982 to treat heroin addicts in Christiania, Denmark, a squatter village where heroin addiction was widespread.[55] Indra extract was available for sale over the Internet until 2006, when the Indra web presence disappeared. Various products are currently sold in a number of countries as "Indra extract", but it is unclear if any of them are derived from Waltenburg's original stock. Ibogaine and related indole compounds are susceptible to oxidation over time.[56][57]

The National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States in the early 1990s, but terminated the project in 1995.[58] Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. in 1999.[59] A cohort of 33 patients were treated with 6 to 29 mg/kg of ibogaine; 25 displayed resolution of the signs of opioid withdrawal from 24 hours to 72 hours post-treatment, but one 24-year-old female, who received the highest dosage, died. Mash et al., (2000) using lower oral doses (10–12 mg/kg) in 27 patients, demonstrated significantly lower objective opiate withdrawal scores in heroin addicts 36 hours after treatment, with self-reports of decreased cocaine and opiate craving and alleviated depression symptoms. Many of these effects appeared sustainable over a one-month post-discharge follow-up.[60]

Society and culture

The Global Ibogaine Therapy Alliance publish a map of ibogaine legal status in various countries around the world.[61]


On 14 January 2016, Ibogaine was legalized for prescription use in São Paulo, Brazil, with this legalization to extend to the rest of the country in a few months.[62]


Ibogaine was unregulated in Canada in 2009.[63][64] Then Health Canada added ibogaine to the Prescription Drug List (PDL) in 2017.[65]


Ibogaine is unregulated in Germany, but for medical use it can be regulated by the pharmacy rules (AMG).

New Zealand

Ibogaine was gazetted in New Zealand in 2009 as a non-approved prescription medicine.[66]


Ibogaine is illegal in Norway (as are all tryptamine derivatives).[67]


Ibogaine is schedule I in Sweden.[68]

United Kingdom

As of January 2017 in the United Kingdom, ibogaine was an unlicensed medical product.[69]

United States

Ibogaine is classified as a Schedule I-controlled substance in the United States,[70] and is not approved there for addiction treatment (or any other therapeutic use) because of its hallucinogenic, neurotoxic, and cardiovascular side effects, as well as the scarcity of safety and efficacy data in human subjects.[71]

Treatment clinics

Ibogaine treatment clinics have emerged in Mexico, Canada, the Netherlands, South Africa, and New Zealand, all operating in what has been described as a "legal gray area".[72][73] Costa Rica also has treatment centers, most notably one run by Lex Kogan, a leading proponent of ibogaine.[74] Covert, illegal neighborhood clinics are known to exist in the United States, despite active DEA surveillance.[75] While clinical guidelines for ibogaine-assisted detoxification were released by the Global Ibogaine Therapy Alliance in 2015,[76][77] addiction specialists warn that the treatment of drug dependence with ibogaine in non-medical settings, without expert supervision and unaccompanied by appropriate psychosocial care, can be dangerous — and, in approximately one case in 300, potentially fatal.[73]


Documentary films

Detox or Die (2004)

Directed by David Graham Scott.[78] David Graham Scott begins videotaping his heroin-addicted friends. Before long, he himself is addicted to the drug. He eventually turns the camera to himself and his family. After 12 years of debilitating, painful dependence on methadone, Scott turns to ibogaine. Filmed in Scotland and England, and broadcast on BBC One as the third instalment in the documentary series One Life.[79]

Ibogaine: Rite of Passage (2004)

Directed by Ben Deloenen.[80] Cy a 34-year-old heroin addict undergoes ibogaine treatment with Dr Martin Polanco at the Ibogaine Association, a clinic in Rosarito Mexico. Deloenen interviews people formerly addicted to heroin, cocaine, and methamphetamine, who share their perspectives about ibogaine treatment. In Gabon, a Babongo woman receives iboga root for her depressive malaise. Deloenen visually contrasts this Western, clinical use of ibogaine with the Bwiti use of iboga root, but emphasizes the Western context.

Facing the Habit (2007)

Directed by Magnolia Martin.[81] Martin's subject is a former millionaire and stockbroker who travels to Mexico for ibogaine treatment for heroin addiction.

Tripping in Amsterdam (2008)

In this short film directed by Jan Bednarz, Simon "Swany" Wan visits Sara Glatt's iboga treatment center in Amsterdam.[82] Current TV broadcast the documentary in 2008, as part of their "Quarter-life Crisis" programming roster.

I'm Dangerous with Love (2009)

Directed by Michel Negroponte.[83] Negroponte examines Dimitri Mugianis's long, clandestine career of treating heroin addicts with ibogaine.

"Hallucinogens" (2012)

In one of five segments from this episode of Drugs, Inc. on National Geographic Channel, a former heroin user treats addicts with ibogaine in Canada. He himself used ibogaine to stop his abuse of narcotics.:[84]

"Addiction" (2013)

This episode of the HBO documentary series Vice[85] devotes a segment to the use of ibogaine to interrupt heroin addiction.

"The Ibogaine Safari" (2014)

A documentary by film maker Pierre le Roux, investigating the claims of painless withdrawal from Opiates such as Njope/Heroin in South Africa by taking several addicts on an adventure 'safari' while taking Ibogaine. The documentary won the award of excellence for 'Best documentary short' at the 2014 Canada International film festival.[86]

While in Wisconsin covering the primary campaign for the United States presidential election of 1972, gonzo journalist Hunter S. Thompson submitted a satirical article to Rolling Stone accusing Democratic Party candidate Edmund Muskie of being addicted to ibogaine. Many readers, and even other journalists, did not realize that the Rolling Stone piece was facetious. The ibogaine assertion, which was completely unfounded, did a significant amount of damage to Muskie's reputation, and was cited as a factor in his loss of the nomination to George McGovern.[87] Thompson later said he was surprised that anyone believed it.[88] The article is included in Thompson's post-election anthology, Fear and Loathing on the Campaign Trail '72 (1973).[89]

Author and Yippie Dana Beal co-wrote the 1997 book The Ibogaine Story.[90]

American author Daniel Pinchbeck wrote about his own experience of ibogaine in his book Breaking Open the Head (2002),[91] and in a 2003 article for The Guardian titled "Ten years of therapy in one night".[92]

Television drama

Ibogaine factors into the stories of these episodes from television drama series:


  • "Sink or Swim. Act Two. I'm Not A Doctor But I Play One At The Holiday Inn.". This American Life. Episode 321. 1 December 2006.  — A former heroin addict realizes that he wants to help other addicts kick their habits. The problem is, he wants to do this using a hallucinogenic drug - ibogaine - that is completely illegal, and which requires medical expertise he doesn't have.[99]


Addiction treatment

The most-studied therapeutic effect of ibogaine is the reduction or elimination of addiction to opioids. An integral effect is the alleviation of symptoms of opioid withdrawal. Research also suggests that ibogaine may be useful in treating dependence on other substances such as alcohol, methamphetamine, and nicotine and may affect compulsive behavioral patterns not involving substance abuse or chemical dependence. Researchers note that there remains a "need for systematic investigation in a conventional clinical research setting."[47]

Many users of ibogaine report experiencing visual phenomena during a waking dream state, such as instructive replays of life events that led to their addiction, while others report therapeutic shamanic visions that help them conquer the fears and negative emotions that might drive their addiction. It is proposed that intensive counseling, therapy and aftercare during the interruption period following treatment is of significant value. Some individuals require a second or third treatment session with ibogaine over the course of the next 12 to 18 months. A minority of individuals relapse completely into opiate addiction within days or weeks. A comprehensive article (Lotsof 1995) on the subject of ibogaine therapy detailing the procedure, effects and aftereffects is found in "Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives".[100] Ibogaine has also been reported in multiple small-study cohorts to reduce cravings for methamphetamine.[101]

There is also evidence that this type of treatment works with LSD, which has been shown to have a therapeutic effect on alcoholism. Both ibogaine and LSD appear to be effective for encouraging introspection and giving the user occasion to reflect on the sources of their addiction, while also producing an intense, transformative experience that can put established patterns of behaviour into perspective;[102] ibogaine has the added benefit of preventing withdrawal effects.[47]

Chronic pain management

In 1957, Jurg Schneider, a pharmacologist at CIBA (now a division of Novartis), found that ibogaine potentiated morphine analgesia.[103] No additional data was ever published by CIBA researchers on ibogaine–opioid interactions. Almost 50 years later, Patrick Kroupa and Hattie Wells released the first treatment protocol for concomitant administration of ibogaine with opioids in human subjects, indicating that ibogaine reduced tolerance to opioid drugs. Their paper in the Multidisciplinary Association for Psychedelic Studies Journal demonstrated that administration of low "maintenance" doses of ibogaine HCl with opioids decreases tolerance, but noted that ibogaine's potentiating action could make this a risky procedure.[104]


Ibogaine has been used as an adjunct to psychotherapy by Claudio Naranjo, documented in his book The Healing Journey.[105] He was awarded patent CA 939266  in 1974.

See also


  1. Canada, Government of Canada, Health. "Notice - Prescription Drug List (PDL): Multiple additions". www.hc-sc.gc.ca.
  2. Galea, Susanna; Lorusso, Mino; Newcombe, David; Walters, Carina; Williman, Jonathon; Wheeler, Amanda (March 2011). Goodyear-Smith, Felicity, ed. "Ibogaine—be informed before you promote or prescribe" (PDF). Journal of Primary Health Care. Royal New Zealand College of General Practitioners. 3 (1): 86. ISSN 1172-6156. Retrieved 4 December 2015.
  3. 1 2 3 4 5 6 Koenig, X; Hilber, K (29 January 2015). "The anti-addiction drug ibogaine and the heart: a delicate relation". Molecules (Basel, Switzerland). 20 (2): 2208–28. doi:10.3390/molecules20022208. PMC 4382526. PMID 25642835.
  4. 1 2 Brown, Thomas (March 2013). "Ibogaine in the treatment of substance dependence". Current Drug Abuse Reviews. 6 (1): 3–16. doi:10.2174/15672050113109990001. PMID 23627782.
  5. Alper, K.R.; Lotsof, H.S.; Kaplan, C.D. (2008). "The Ibogaine Medical Subculture". J. Ethnopharmacol. 115 (1): 9–24. doi:10.1016/j.jep.2007.08.034. PMID 18029124. Archived from the original on 6 February 2008. Retrieved 22 February 2008.
  6. Hamilton, Keegan (17 November 2010). "Ibogaine: Can it Cure Addiction Without the Hallucinogenic Trip?". The Village Voice.
  7. Alper, Kenneth R. (2001). "Chapter 1: Ibogaine: A Review". In Alper, Kenneth R.; Glick, Stanley D. Ibogaine : proceedings from the first international conference. The Alkaloids. 56. Academic. pp. 2–33. ISBN 9780120532063.
  8. Chris Jenks: Extracting Ibogaine Chris Jenks tells about the findings of his Extraction Studies.
  9. Iboga Extraction Manual Compiled 2009 by Dr. Chris Jenks.
  10. US patent 2813873, Morrice-Marie Janot & Robert Goutarel, "Derivatives of the ibogaine alkaloids", issued 19 November 1957, assigned to Les Laboratoires Gobey
  11. Soriano-García, M.; Walls, F.; Rodríguez, A.; López Celis, I. (1988). "Crystal and molecular structure of ibogamine: An alkaloid from Stemmadenia galeottiana". Journal of Crystallographic and Spectroscopic Research. 18 (2): 197–206. doi:10.1007/BF01181911.
  12. Arai, G.; Coppola, J.; Jeffrey, G. A. (1960). "The structure of ibogaine". Acta Crystallographica. 13 (7): 553–564. doi:10.1107/S0365110X60001369.
  13. Alper, Kenneth R.; Beal, Dana; Kaplan, Charles D. (2001). A CONTEMPORARY HISTORY OF IBOGAINE IN THE UNITED STATES AND EUROPE (PDF). Academic Press. p. 256.
  14. Obembe, Samuel (2012). Practical Skills and Clinical Management of Alcoholism & Drug Addiction. Elsevier. p. 88. ISBN 9780123985187. Retrieved 6 September 2012.
  15. Vastag, B (15 April 2005). "Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'". Science. 308 (5720): 345–346. doi:10.1126/science.308.5720.345. PMID 15831735.
  16. "Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial". clinicaltrials.gov.
  17. 1 2 3 Jenks, C. (2002). "Extraction Studies of Tabernanthe Iboga and Voacanga Africana". Natural Product Letters. 16 (1): 71–76. doi:10.1080/1057563029001/4881. PMID 11942686.
  18. 1 2 Alper, Kenneth; Bai, Rong; Liu, Nian; Fowler, Steven J.; Huang, Xi-Ping; Priori, Silvia G.; Ruan, Yanfei (1 January 2016). "hERG Blockade by Iboga Alkaloids". Cardiovascular Toxicology. 16 (1): 14–22. doi:10.1007/s12012-015-9311-5. ISSN 1530-7905. PMID 25636206.
  19. O'Hearn, E.; Molliver, M. E. (1 July 1993). "Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline". Neuroscience. 55 (2): 303–310. doi:10.1016/0306-4522(93)90500-f. ISSN 0306-4522. PMID 8377927.
  20. 1 2 Mash, D. C.; Kovera, C. A.; Buck, B. E.; Norenberg, M. D.; Shapshak, P.; Hearn, W. L.; Sanchez-Ramos, J. (30 May 1998). "Medication development of ibogaine as a pharmacotherapy for drug dependence". Annals of the New York Academy of Sciences. 844: 274–292. doi:10.1111/j.1749-6632.1998.tb08242.x. ISSN 0077-8923. PMID 9668685.
  21. Scallet, A. C.; Ye, X.; Rountree, R.; Nony, P.; Ali, S. F. (31 October 1996). "Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Neurohistological biomarkers of Purkinje cell loss". Annals of the New York Academy of Sciences. 801: 217–226. doi:10.1111/j.1749-6632.1996.tb17444.x. ISSN 0077-8923. PMID 8959036.
  22. Bowen, WD (2001). "Sigma receptors and iboga alkaloids". The Alkaloids. Chemistry and biology. 56: 173–191.
  23. 1 2 Alper, Kenneth R.; Glick, Stanley D. (2001). "Ibogaine: A Review". The alkaloids: chemistry and biology (PDF). 56. San Diego: Academic. pp. 1–38. ISBN 0-12-469556-6. Archived from the original on 27 September 2007.
  24. 1 2 Alper, Kenneth R.; Stajić, Marina; Gill, James R. (1 March 2012). "Fatalities Temporally Associated with the Ingestion of Ibogaine". Journal of Forensic Sciences. 57 (2): 398–412. doi:10.1111/j.1556-4029.2011.02008.x. ISSN 1556-4029. PMID 22268458.
  25. "Grapefruit juice: Beware of dangerous medication interactions". Retrieved 10 September 2010.
  26. Glick SD, Maisonneuve IM, Szumlinski KK (2001). "Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener" (PDF). Alkaloids Chem Biol. The Alkaloids: Chemistry and Biology. 56: 39–53. doi:10.1016/S0099-9598(01)56006-X. ISBN 9780124695566. PMID 11705115.
  27. Litjens RP, Brunt TM (2016). "How toxic is ibogaine?". Clin Toxicol. 54 (4): 297–302. doi:10.3109/15563650.2016.1138226. PMID 26807959.
  28. Popik, P.; Skolnick, P. (1998). G.A. Cordell, ed. "Pharmacology of Ibogaine and Ibogaine-Related Alkaloids". The Alkaloids. The Alkaloids: Chemistry and Biology. Academic Press. 52: 197–231. doi:10.1016/s0099-9598(08)60027-9. ISBN 9780124695528. Archived from the original on 26 May 2012.
  29. Maillet, Emeline L.; Milon, Nicolas; Heghinian, Mari D.; Fishback, James; Schürer, Stephan C.; Garamszegi, Nandor; Mash, Deborah C. (21 August 2015). "Noribogaine is a G-protein biased κ-opioid receptor agonist". Neuropharmacology. 99 (December 2015): 675–88. doi:10.1016/j.neuropharm.2015.08.032. PMID 26302653.
  30. Noribogaine is a G-protein biased κ-opioid receptor agonist. Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC. Neuropharmacology |date=December 2015 |99:675-88. doi:10.1016/j.neuropharm.2015.08.032. Epub 2015 Aug 21. PMID 26302653
  31. Antonio T, Childers SR, Rothman RB, et al. (2013). "Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation". PLoS ONE. 8 (10): e77262. doi:10.1371/journal.pone.0077262. PMC 3818563. PMID 24204784.
  32. Zubaran C, Shoaib M, Stolerman IP, Pablo J, Mash DC (July 1999). "Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain". Neuropsychopharmacology. 21 (1): 119–26. doi:10.1016/S0893-133X(99)00003-2. PMID 10379526.
  33. Baumann MH, Rothman RB, Pablo JP, Mash DC (2001). "In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats". J. Pharmacol. Exp. Ther. 297 (2): 531–9. PMID 11303040.
  34. Hough LB, Bagal AA, Glick SD (2000). "Pharmacokinetic characterization of the indole alkaloid ibogaine in rats". Methods Find Exp Clin Pharmacol. 22 (2): 77–81. doi:10.1358/mf.2000.22.2.796066. PMID 10849889.
  35. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., Singleton, E. G., Mayor, M. . (2000). "Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures". Ann N Y Acad Sci. 914: 394–401. doi:10.1111/j.1749-6632.2000.tb05213.x. PMID 11085338.
  36. Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL. p. 487.
  37. Jana, G. K.; Sinha, S. (2012). "Total synthesis of ibogaine, epiibogaine and their analogues". Tetrahedron. 68 (35): 7155–7165. doi:10.1016/j.tet.2012.06.027.
  38. "Voacanga Extraction Manual: Phase 4: Production and Purification of Ibogaine" (PDF). www.puzzlepiece.org. Retrieved 4 December 2015.
  39. Pace CJ; Glick SD; Maisonneuve IM; He, Li-Wen; Jokiel, Patrick A.; Kuehne, Martin E.; Fleck, Mark W. (2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". Eur. J. Pharmacol. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.
  40. Glick SD; Kuehne ME; Raucci J; Wilson, T.E.; Larson, D.; Keller, R.W.; Carlson, J.N. (1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Res. 657 (1–2): 14–22. doi:10.1016/0006-8993(94)90948-2. PMID 7820611.
  41. Tsing Hua (28 January 2006). "Antiaddictive indole alkaloids in Ervatamia yunnanensis and their bioactivity". Academic Journal of Second Military Medical University. Retrieved 15 August 2012.
  42. Dybowski, J.; Landrin, E. (1901). "PLANT CHEMISTRY. Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it contains, ibogaine". C. R. Acad. Sci. 133: 748.
  43. Büchi, G.; Coffen, D.L.; Kocsis, Karoly; Sonnet, P.E.; Ziegler, Frederick E. (1966). "The Total Synthesis of Iboga Alkaloids" (PDF). J. Am. Chem. Soc. 88 (13): 3099–3109. doi:10.1021/ja00965a039.
  44. Frauenfelder, Christine (1999). Doctoral Thesis (Thesis). p. 24. Archived from the original (PDF) on 17 August 2012.
  45. Ibogaine: A Novel Anti-Addictive Compound – A Comprehensive Literature Review Jonathan Freedlander, University of Maryland Baltimore County, Journal of Drug Education and Awareness, 2003; 1:79–98.
  46. Ibogaine – Scientific Literature Overview The International Center for Ethnobotanical Education, Research & Service (ICEERS) 2012
  47. 1 2 3 Alper, K.R.; Lotsof, H.S.; Frenken, G.M.; Luciano, D.J.; Bastiaans, J. (1999). "Treatment of Acute Opioid Withdrawal with Ibogaine" (PDF). The American Journal on Addictions. 8 (3): 234–42. doi:10.1080/105504999305848. PMID 10506904. Archived from the original (PDF) on 26 January 2002. Retrieved 16 June 2009.
  48. Hevesi, Dennis (17 February 2010). "Howard Lotsof Dies at 66; Saw Drug Cure in a Plant". The New York Times. ISSN 0362-4331. Retrieved 11 June 2015.
  49. Dzoljic ED, Kaplan CD, Dzoljic MR (1988). "Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats". Arch Int Pharmacodyn Ther. 294: 64–70. PMID 3233054.
  50. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991). "Effects and aftereffects of ibogaine on morphine self-administration in rats". Eur. J. Pharmacol. 195 (3): 341–345. doi:10.1016/0014-2999(91)90474-5. PMID 1868880.
  51. Cappendijk SL, Dzoljic MR (1993). "Inhibitory effects of ibogaine on cocaine self-administration in rats". European Journal of Pharmacology. 241 (2–3): 261–265. doi:10.1016/0014-2999(93)90212-Z. PMID 8243561.
  52. Rezvani A, Overstreet D, Lee Y (1995). "Attenuation of alcohol intake by ibogaine in three strains of alcohol preferring rats". Pharmacology Biochemistry and Behavior. 52 (3): 615–20. doi:10.1016/0091-3057(95)00152-M. PMID 8545483.
  53. "A Home for Ibogaine in Barcelona". The Huffington Post. Retrieved 11 June 2015.
  54. "Costa Rican Center a Leader in Alernative Ibogaine Therapy - Treatment Magazine". www.treatmentmagazine.com. Retrieved 11 June 2015.
  55. Alper, Kenneth R.; Beal, Dana; Kaplan, Charles D. "A Contemporary History of Ibogaine in the United States and Europe". Ibogaine: Proceedings of the First International Conference. The Alkaloids. 56. Retrieved 15 August 2012.
  56. Kontrimaviciūte V; Mathieu O; Mathieu-Daudé JC; Vainauskas, P; Casper, T; Baccino, E; Bressolle, FM (September 2006). "Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub". J Anal Toxicol. 30 (7): 434–40. doi:10.1093/jat/30.7.434. PMID 16959135.
  57. Taylor WI (1965). "The Iboga and Voacanga Alkaloids". The Alkaloids: Chemistry and Physiology (PDF). pp. 203, 207–208.
  58. Doblin, Rick. "A Non-Profit Approach to Developing Ibogaine into an FDA-Approved Medication" (ppt). Retrieved 16 August 2012.
  59. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). "Treatment of acute opioid withdrawal with ibogaine" (PDF). Am J Addict. 8 (3): 234–42. doi:10.1080/105504999305848. PMID 10506904. Archived from the original (PDF) on 2002-01-26.
  60. Mash DC; Kovera CA; Pablo J; Tyndale, Rachel F.; Ervin, Frank D.; Williams, Izben C.; Singleton, Edward G.; Mayor, Manny (September 2000). "Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures" (PDF). Ann. N. Y. Acad. Sci. 914: 394–401. doi:10.1111/j.1749-6632.2000.tb05213.x. PMID 11085338.
  61. "Ibogaine Legal Status". The Global Ibogaine Therapy Alliance. Retrieved 2017-09-26.
  63. Johnson, Gail (2 January 2003). "Ibogaine: A one-way trip to sobriety, pot head says". straight.com. Retrieved 5 November 2009.
  64. "Controlled Drugs and Substances Act". Canadian Department of Justice. 1996. Retrieved 5 November 2009.
  65. Canada, Government of Canada, Health. "Notice - Prescription Drug List (PDL): Multiple additions". www.hc-sc.gc.ca.
  66. "Archived copy". Archived from the original on 13 May 2014. Retrieved 12 May 2014.
  67. "Forskrift om narkotika (narkotikaforskriften)". lovdata.no. Retrieved 24 March 2015.
  68. "Lakemedelsverkets forfattningssamling" (PDF). lakemedelsverket.se.
  69. Carr, Stewart (31 January 2017). "Fake 'experts' jailed after heroin user dies in Luton clinic". Luton Today.
  70. "Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). Retrieved 23 August 2012.
  71. Ibogaine. Basic data - drugwarfacts.org Retrieved 17 June 2015
  72. Hegarty, S. (13 April 2012). Can a hallucinogen from Africa cure addiction? BBC News archive. Retrieved 17 June 2015.
  73. 1 2 Ibogaine therapy for drug addiction. maps.org archive. Retrieved 17 June 2015.
  74. "Costa Rican Center a Leader in Alternative Ibogaine Therapy". Treatment Magazine. 11 September 2012. Retrieved 27 November 2013.
  75. Hunter, A. (13 December 2005). Busted for Iboga. Village Voice Retrieved 17 June 2015.
  76. Clinical Guidelines for Ibogaine-Assisted Detoxification. Retrieved 25 August 2015
  77. "Global Ibogaine Therapy Alliance".
  78. Detox or Die (2004) on IMDb
  79. Detox or Die at the British Film Institute
  80. Ibogaine: Rite of Passage (2004) on IMDb
  81. Facing the Habit (2007) on IMDb
  82. "Tripping in Amsterdam". Current.com. 23 June 2008. Retrieved 7 April 2013.
  83. Dangerous with Love (2009) on IMDb
  84. "Hallucinogens" on IMDb
  85. "Addiction" on IMDb
  86. Ibogaine safari, IT IS SOMETHING TO WITNESS! The Trailer. YouTube. 30 May 2013. Retrieved 24 March 2015.
  87. Remembering Ed Muskie", Online NewsHour, PBS, 26 March 1996.
  88. Gibney, Alex (2008). Gonzo: The Life and Work of Dr. Hunter S. Thompson (Motion picture). OCLC 259718859.
  89. Fear and Loathing on the Campaign Trail '72. Straight Arrow Books. 1973. pp. 150–54. ISBN 978-0-87932-053-9. OCLC 636410.
  90. Beal D and De Rienzo P. The Ibogaine Story: Report on the Staten Island Project. Autonomedia (1997). ISBN 1570270295
  91. Pinchbeck, Daniel (2002). Breaking Open the Head: A Psychedelic Journey into the Heart of Contemporary Shamanism. Broadway Books. ISBN 9780767907422. OCLC 50601753.
  92. Pinchbeck, Daniel (19 September 2003). "Ten years of therapy in one night". The Guardian. London. Retrieved 15 December 2013.
  93. "Via Negativa" on IMDb
  94. "Getting Off" on IMDb
  95. "Users" on IMDb
  96. "Echoes" on IMDb
  97. "Horse and Wagon" on IMDb
  98. "Bon Voyage" on IMDb
  99. Olkowski, Lu; Kay, Trey (1 December 2006). "Sink or Swim. Act Two. I'm Not A Doctor But I Play One At The Holiday Inn.". This American Life. Episode 321. 16 minutes in. Retrieved 17 August 2015.
  100. Lotsof, H.S. (1995). "Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives". 3. MAPS Bulletin: 19–26. Archived from the original on 22 January 1997.
  101. Giannini, A. James (1997). Drugs of Abuse (2 ed.). Practice Management Information Corporation. ISBN 1-57066-053-0.
  102. Ludwig, A.; Levine, J.; Stark, L.; Lazar, R. (1969). "A clinical study of LSD treatment in alcoholism". The American Journal of Psychiatry. 126 (1): 59–69. doi:10.1176/ajp.126.1.59. PMID 5798383.
  103. US patent 2817623, Jurg Schneider, "Tabernanthine, Ibogaine Containing Analgesic Compositions.", issued 1957-12-24, assigned to CIBA Pharmaceuticals Inc.
  104. Kroupa, Patrick K.; Wells, Hattie (2005). "Ibogaine in the 21st Century" (PDF). XV (1). Multidisciplinary Association for Psychedelic Studies: 21–25.
  105. Naranjo, Claudio (1973). "V, Ibogaine: Fantasy and Reality". The healing journey: new approaches to consciousness. New York: Pantheon Books. pp. 197–231. ISBN 0-394-48826-1. Archived from the original on 17 July 2001. Retrieved 15 August 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.